Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7207643 | 0.79 | FABP3 (0.33) | ALDH1A1CYP3A4FABP3FABP4HSD17B10 | |
| SCHEMBL7108814 | 0.79 | FABP3 (0.41) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL7104863 | 0.78 | FABP3 (0.40) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL8495041 | 0.77 | FABP3 (0.49) | ALDH1A1CYP3A4FABP3FABP4FABP5 | |
| SCHEMBL7762115 | 0.74 | PPARG (0.34) | ALDH1A1CYP3A4PPARG | |
| SCHEMBL5469738 | 0.72 | FABP3 (0.40) | FABP3FABP4FABP5 | |
| SCHEMBL7206928 | 0.68 | FABP3 (0.41) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL6936873 | 0.68 | FABP3 (0.31) | FABP3FABP4 | |
| SCHEMBL7206870 | 0.68 | SRD5A2 (0.39) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL8706010 | 0.68 | FABP3 (0.38) | FABP3FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841913-B1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | EP | claimed |